Stefan Pflanz

Executive Director Boehringer-Ingelheim Venture Fund USA

2020 - Current

BoD roles: Actym; https://www.actymthera.com/; 2020 - present Bodyport; https://www.bodyport.com/; 2021 - present Oncomyx; https://www.oncomyx.com/; 2020 - 2023 TigaTx; https://www.tigatx.com; 2021 -present

Director Cancer Immunology and Immune Modulation

2016 - 2020

Senior Research Scientist

2011 - 2016

Visiting Scientist in Department of Dermatology

2010 - 2011

Performed experiments interrogating neuro-immune networks involved in regulation of inflammatory skin diseases.

Head of Cytokine Biology

2006 - 2010

Led target identification and validation research with a focus on biologics for therapeutic modulation of immune-related cytokine pathways. Managed a research lab with four direct reports and eight project-related reports in support labs. Reported to Site Head.

Head of Target Research

2004 - 2006

Supervised target identification research and target validation efforts around molecules suitable for therapeutic intervention with antibodies or antibody fragments in the areas of inflammation and oncology. Bore responsibility for optimization of lead candidate antibody molecules according to desired specifications. Managed Target Research Team with five direct reports. Reported to CSO.

Group Leader SCA Therapeutics

2003 - 2004

Oversaw identification and characterization of therapeutic single chain antibodies (SCAs) for treatment of inflammatory disorders. Managed three direct reports. Reported to SCA Unit Head.

Postdoctoral Fellow

2000 - 2002

Discovered and first characterized novel cytokine Interleukin-27.

PhD student

1996 - 1999